Stereotaxis Gets Capital Infusion, Eyes ‘Strategic’ Alternatives

Stereotaxis Inc. announced it has received a capital infusion of $8.5 million but said the cash won’t fix its long-term liquidity challenge. To deal with that, the St. Louis-based medical device manufacturer has hired Gordian Group LLC to help it evaluate “various strategic and financing alternatives.”

The fresh capital comes after noteholders of the Stereotaxis convertible debt exercised warrants for 5.2 million shares, increasing the amount of outstanding stock by roughly 65 percent.

Read more from the St. Louis Post-Dispatch


Leave a Reply